HOME >> BIOLOGY >> NEWS
Forensics bringing bacteria into the courtroom

DENVER, CO If bioterrorists are ever brought to trial, the evidence against them will depend on the painstaking work of a detective in a lab coat.

But will it be worth the effort?

Scientists at the annual meeting of the American Association for the Advancement of Science (AAAS) warn that such evidence will not be admissible unless researchers develop new molecular methods, such as genome sequencing, and adopt standardized methods and data.

"Today, there are cases that are more likely to come up in court. As a discipline, we need to be prepared," said Abigail Salyers, of the University of Illinois at Urbana-Champaign. "Let's be thinking ahead so we don't have an O.J. Simpson situation where the validity of the tests used to gather certain evidence (becomes) the focal point of a trial. We must put into place quality control and standards that provide proper validation and interpretation, so microbial evidence involving genetic information will be viewed acceptable in a courtroom."

Citing the recent attacks of anthrax sent through the mail, and the potential for other acts of bioterrorism, Salyers and her colleagues at a session held during the AAAS Annual Meeting called for the development of a comprehensive microbial forensics infrastructure.

In microbial forensics, researchers work to track down the source of a pathogen, whether in a criminal investigation of bioterrorism attacks or a study of naturally occurring disease outbreak, looking for molecular microbial signatures. These signatures are detected by measuring the polymorphisms, or variations, between microbial strains and are used to infer the origin, relationship, or transmission route of a particular isolate.

Recently, microbial forensics has been used in cases such as the alleged transmission of HIV from a Florida dentist to several patients. By sequencing viral fragments from the dentist and infected patients, they were able show that he most likely infecte
'"/>


16-Feb-2003


Page: 1 2 3

Related biology news :

1. Life and death struggle: Proteins play against each other, bringing balance to immune system
2. Researchers find color sensitive atomic switch in bacteria
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
5. Scientists discover potential new way to control drug-resistant bacteria
6. 22nd amino acid synthesized and added to genetic code of e. coli bacteria
7. Missing genes may help explain why plague bacteria are so deadly
8. Complex cells likely arose from combination of bacterial and extreme-microbe genomes
9. Stuck on you: Scientists lay bare secrets of bacterial attachment proteins
10. UC Irvine scientists to develop vaccine to combat bioterrorism threat from deadly bacteria
11. UV light, coatings reduce bacterial adhesion up to 50 percent

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Forensics bringing bacteria into the courtroom

(Date:5/21/2013)... at Chicago College of Medicine will study gender differences in ... energy source -- and how changes in fat metabolism play ... 4-year grant from the National Heart, Lung and Blood Institute. ... for energy. These changes may play a major role in ... and women, says E. Douglas Lewandowski, director of the UIC ...
(Date:5/21/2013)... charted the path of insulin action in cells in ... blueprint for understanding what goes wrong in diabetes. ... Professor David James from Sydney,s Garvan Institute of Medical ... of the prestigious journal Cell Metabolism . , ... very important role in the body because it helps ...
(Date:5/20/2013)... is known about the effect of physical education (PE) ... University finds that increasing the amount of time that ... of obesity. , The study represents some of the ... youth obesity, and is forthcoming in the Journal ... of the study can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Gym class reduces probability of obesity, study finds for first time 2
(Date:5/21/2013)... May 21, 2013 Alpha Source, ... , will be exhibiting for the 13th consecutive ... Medical Instrumentation (AAMI) 2013 Conference and Expo. The ... distribute, and manufacture healthcare technologies. This year’s event ... Beach, California. , The three-day event draws ...
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 As ... a strong push within the industry to deliver ... Manufacturing Organizations and pharma companies often means turning ... , Microtablets, developed in collaboration with Sensidose AB ... outsourcing can bring products to market sooner. The ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: